Search and filter adverse-event reports.
1,929,324 reports(834 ms)
consumer received 3 doses of GARDASIL-9 at 8 years old, 8 years and 6 months old, and 9 year and 7 months old.; No additional AE reported; d 3 doses of GARDASIL-9 at 8 years old, 8 years and 6 months old, and 9 year and 7 months old; d 3 doses of GARDASIL-9 a…
No additional AE/PQC; HCP called and reported inadvertent administration of expired VARIVAX to a patient.; This spontaneous report was received from a medical assistant and refers to a patient of unknown age and gender. Limited patient demographics were provid…
HCP reported that patient was administered the 1st and 2nd dose of ROTATEQ, but has not yet been administered the 3rd dose; No additional AE; This spontaneous report was received from a nurse and refers to a patient of unknown gender, 34-weeks-old at the time…
No additional AE /PQC reported; HCP calling to report T/E; Information has been received from Business Partner/CRO on 10-Apr-2025. This spontaneous report was received from a Nurse and refers to a 3-year-old patient of unknown gender. The patient's medical h…
Patient involved has not reported any medical concerns or symptoms/ No additional AE/PQC.; Expired dose of VARIVAX that was administered; This spontaneous report was received from a medical assistant, regarding a patient of unknown age and gender. The patient'…
Drug Interaction with Burton tyrosine kinase inhibitors (BTKi's); HEPLISAV-B given at 0 and 3 months; Median anti-HBS titer was 0.05 mIU/mL with BTKi treatment; Initial report received on 21-Mar-2025. This report was retrieved from a publication: The patie…
Drug Interaction with Burton tyrosine kinase inhibitors (BTKi's); HEPLISAV-B given at 0 and 3 months; Median anti-HBS titer was 0.05 mIU/mL with BTKi treatment; Initial report received on 21-Mar-2025. This report was retrieved from a publication. The patient…
Drug Interaction with Burton tyrosine kinase inhibitors (BTKi's); HEPLISAV-B given at 0 and 3 months; Median anti-HBS titer was 0.05 mIU/mL with BTKi treatment; Initial report received on 21-Mar-2025. This report was retrieved from a publication. The patient…
Drug Interaction with Burton tyrosine kinase inhibitors (BTKi's); HEPLISAV-B given at 0 and 3 months; Median anti-HBS titer was 0.05 mIU/mL with BTKi treatment; Initial report received on 21-Mar-2025. This report was retrieved from a publication. The patient…
Drug Interaction with Burton tyrosine kinase inhibitors (BTKi's); HEPLISAV-B given at 0 and 3 months; Median anti-HBS titer was 0.05 mIU/mL with BTKi treatment; Initial report received on 21-Mar-2025. This report was retrieved from a publication. The patient…
Drug Interaction with Burton tyrosine kinase inhibitors (BTKi's); HEPLISAV-B given at 0 and 3 months; Median anti-HBS titer was 0.05 mIU/mL with BTKi treatment; Initial report received on 21-Mar-2025. This report was retrieved from a publication. The patient…
Drug Interaction with Burton tyrosine kinase inhibitors (BTKi's); HEPLISAV-B given at 0 and 3 months; Median anti-HBS titer was 0.05 mIU/mL with BTKi treatment; Initial report received on 21-Mar-2025. This report was retrieved from a publication. The patient…
Drug Interaction with Burton tyrosine kinase inhibitors (BTKi's); HEPLISAV-B given at 0 and 3 months; Median anti-HBS titer was 0.05 mIU/mL with BTKi treatment; Initial report received on 21-Mar-2025. This report was retrieved from a publication. The patient…
Drug Interaction with Burton tyrosine kinase inhibitors (BTKi's); HEPLISAV-B given at 0 and 3 months; Median anti-HBS titer was 0.05 mIU/mL with BTKi treatment; Initial report received on 21-Mar-2025. This report was retrieved from a publication. The patient…
Drug Interaction with Burton tyrosine kinase inhibitors (BTKi's); HEPLISAV-B given at 0 and 3 months; Median anti-HBS titer was 0.05 mIU/mL with BTKi treatment; Initial report received on 21-Mar-2025. This report was retrieved from a publication The patient…
Drug Interaction with Burton tyrosine kinase inhibitors (BTKi's); HEPLISAV-B given at 0 and 3 months; Median anti-HBS titer was 0.05 mIU/mL with BTKi treatment; Initial report received on 21-Mar-2025. This report was retrieved from a publication. The patient…
never received the second dose; This non-serious case was reported by a consumer via call center representative and described the occurrence of incomplete course of vaccination in a male patient who received Herpes zoster (Shingrix) for prophylaxis. Previous…
Arm was really sore; This non-serious case was reported by a other health professional via sales rep and described the occurrence of pain in arm in a 25-year-old female patient who received Men B NVS (Meningococcal B vaccine) for prophylaxis. On an unknown d…
received third dose of Shingrix; 2nd dose administered on 31 January 2025; This non-serious case was reported by a other health professional via sales rep and described the occurrence of extra dose administered in a 56-year-old female patient who received Herp…
patient received the first dose of SHINGRIX 29 DEC 2022 and the second dose of SHINGRIX 11 APR 2025; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in…